Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q1 2022 · 10-Q
Revenue$380.00K$380.00K−66.2% vs Q1 2021 Net Income-$10.29M-$10.29MN/M vs Q1 2021 EPS Diluted-$0.11-$0.11N/M vs Q1 2021 Gross Profit$247,000+212.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flow-$13,277,000N/M Free Cash Flowderived-$14,838,000N/M Margins · derivedGross margin65.0%+58.0 pt vs Q1 2021
Operating margin-793.9%+216.7 pt vs Q1 2021
Net margin-2708.2%−2359.5 pt vs Q1 2021
ended Mar 31, 2022 · filed May 12, 2022 · 42 d after period end